Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysis
From the perspective of the Chinese healthcare system, biologics are estimated to be cost-effective compared to SoC. Among these, SEC is the most cost-effective option.
Authors
- Yan Ge (ORCID: https://orcid.org/0000-0003-4378-6990)
- Mei-Yu Wu (ORCID: https://orcid.org/0009-0005-4991-4422)
- Ouyang Xie
- Heng Xiang
- Chongqing Tan (ORCID: https://orcid.org/0000-0002-6007-4170)
- Liubao Peng
- Andong Li (ORCID: https://orcid.org/0000-0001-5291-2720)
- Kehui Meng
- Xiaomin Wan
Institutions
- Central South University (CN)
- Autoimmune Technologies (United States) (US)
- Second Xiangya Hospital of Central South University (CN)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1080/14737167.2025.2451740
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- China Primary Health Care Foundation
- Natural Science Foundation of Hunan Province